The "Shark Tank" investor and Cost Plus Drugs cofounder Dr. Alex Oshmyansky participated in a White House health care ...

The billionaire entrepreneur spoke to Fortune after participating in a White House roundtable discussion on bringing ...

Pharmacy benefit managers (PBMs) “invent all these special categories,” Cuban told Fortune’s Andrew Nusca. “They’re just ...

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...

At the Fortune Brainstorm Tech Dinner Mark Cuban discusses his efforts to disrupt the pharmaceutical industry through Cost Plus Drugs, focusing on transparency in pricing and lowering drug costs.

Can Walgreens Boots Alliance stock continue rising, or should investors use the stock's recent gain as an opportunity to exit ...

Likewise, the Mark Cuban Cost Plus Drug Company, is doing something similar, selling a version of Humira for $584 for cash-paying customers without involving a PBM. Typically, PBMs are the ...

Plus Oceans Healthcare adds five states with acquisition and UTA professor leads $1.8 million study.

He's played an active role in his drug-pricing startup, which launched as the Mark Cuban Cost Plus Drug Co. in 2021. Truepill struggled to keep up with Cuban's drug company Truepill works with a ...

The pharmaceutical landscape enters 2025 with a mix of challenges and opportunities, with the potential to shape the future ...

A report from the Federal Trade Commission (FTC) has determined that pharmacy benefit managers (PBMs) are linked to significant cost increases for cancer, HIV, and other critical specialty drugs.

A new study examining the use of high-cost drugs among patients with colorectal cancer and non-small cell lung cancer found ...